December 5, 2014 : Episode 4

Video

Analyzing CTCs Using Next-Generation Sequencing

Related Videos
Suresh S. Ramalingam, MD, FACP, FASCO, professor, Department of Hematology and Medical Oncology, Roberto C. Goizueta Distinguished Chair for Cancer Research, Emory University School of Medicine, executive director, Winship Cancer Institute of Emory University, associate vice president, cancer, Woodruff Health Sciences Center
Byoung Chol Cho, MD, PhD, professor, internal medicine, Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine
Stephen J. Freedland, MD
Ben Levy, MD, and Yan Leyfman, MD
BDTX-1535 – A MasterKey EGFR Inhibitor Targeting Classical, Non-Classical, and the C797S Resistance Mutation To Address The Evolved Landscape Of EGFR Mutant NSCLC
Timothy Yap, MBBS, PhD, FRCP
C. Ola Landgren, MD, PhD
Video 14 - "Key Takeaways in HER2-Mutated NSCLC"
Video 13 - "Treatment Considerations in HER2-Mutated NSCLC"
Related Content
Taletrectinib in ROS1-positive non–small cell lung cancer: © stock.adobe.com
June 2nd 2024

Taletrectinib Yields Durable Responses in TKI Naive and Crizotinib Pretreated ROS1+ NSCLC

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Ana C. Garrido-Castro, MD, a medical oncologist and codirector of the Triple-Negative Breast Cancer Working Group at Dana-Farber Cancer Institute and assistant professor of medicine at Harvard Medical School
June 2nd 2024

Pembrolizumab Plus Sacituzumab Govitecan Shows Nonsignificant Trend Toward Improved PFS in HR+ Breast Cancer

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

David R. Spigel, MD, of Sarah Cannon Research Institute
June 2nd 2024

Consolidation Durvalumab to Become New SOC for LS-SCLC After Chemoradiation

Suresh S. Ramalingam, MD, FACP, FASCO
June 2nd 2024

Osimertinib Could Alter SOC for Stage III EGFR+ NSCLC